14
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      PM384. The effect of brexpiprazole (OPC-34712) versus aripiprazole in adult patients with acute schizophrenia: an exploratory study

      abstract
      International Journal of Neuropsychopharmacology
      Oxford University Press

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Leslie Citrome MD, MPH 1 , Ai Ota BSc 2 , Kazuhiro Nagamizu BSc 2 , Pamela Perry MSc 3 , Emmanuelle Weiller PsyD 4 , Ross Baker PhD MBA 3 1 New York Medical College, Valhalla, NY, USA 2 Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan 3 Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ, USA 4 H. Lundbeck A/S, Valby, Denmark Abstract Background: Brexpiprazole is a serotonin-dopamine activity modulator that acts as a partial agonist at 5-HT1A and dopamine D2 receptors, and an antagonist at 5-HT2A and noradrenaline alpha1B/2C receptors, all at similar potencies. Brexpiprazole has lower intrinsic activity at the D2 receptor than aripiprazole, suggesting a lower potential to induce D2 agonist-mediated adverse events such as akathisia, insomnia, restlessness, and nausea. In this open-label study the effects of 6-week treatment with brexpiprazole or aripiprazole in patients with schizophrenia were explored (NCT02054702). Methods: Patients with an acute relapse of schizophrenia were randomized to receive brexpiprazole 1 to 4mg/day (3mg/day target dose) or aripiprazole 10 to 20 mg/day (15 mg/day target dose) for 6 weeks. The mean change in Positive and Negative Syndrome Scale (PANSS) total score from baseline to Week 6 was analysed. Results: A total of 97 patients were treated with brexpiprazole (N=64) or aripiprazole (N=33). A reduction in the symptoms of schizophrenia assessed by the PANSS total score were observed in both treatment groups (LS mean change at week 6: -22.9 and -19.4 for brexpiprazole and aripiprazole, respectively). Brexpiprazole was well tolerated and the incidence of EPS-related adverse events including akathisia was lower in the patients treated with brexpiprazole (14.1%) compared with the patients treated with aripiprazole (30.3%). Conclusion: Clinically relevant improvements in psychopathology were observed in patients with acute schizophrenia treated with brexpiprazole or aripiprazole. Brexpiprazole was well tolerated with a lower incidence of EPS-related adverse events than aripiprazole.

          Related collections

          Author and article information

          Journal
          Int J Neuropsychopharmacol
          Int. J. Neuropsychopharmacol
          ijnp
          International Journal of Neuropsychopharmacology
          Oxford University Press (US )
          1461-1457
          1469-5111
          June 2016
          27 May 2016
          : 19
          : Suppl 1
          : 40-41
          Article
          pyw041.384
          10.1093/ijnp/pyw041.384
          5616320
          e3aa777c-fcfd-42f4-9aaa-56ffa6269c3c
          © The Author 2016. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.
          History
          Page count
          Pages: 2
          Categories
          Abstracts
          Monday Abstracts

          Pharmacology & Pharmaceutical medicine
          Pharmacology & Pharmaceutical medicine

          Comments

          Comment on this article